The interim recommendations made by the National Drug Scheduling Advisory Committee (NDSAC) on June 2, 2024 that:
- Desloratadine and its salts and preparations in products labelled for use in children aged 2 to 11 years, in package sizes containing greater than 35mg of desloratadine, remain in Schedule III
- Desloratadine and its salts and preparations in products labelled for use in children aged 2 to 11 years, in package sizes containing no more than 35mg of desloratadine, be granted Unscheduled status
were finalized effective July 23, 2024. Final approval of the interim recommendations was made by NAPRA’s Board of Directors. In this case, NAPRA did not receive any comments during the 30-day consultation period. The National Drug Schedules will be revised accordingly.
Subscribe to Updates from NAPRA
Receive NAPRA updates of interest directly to your inbox: general NAPRA news, NDS updates and/or updates on practice resources.